Cargando…
The Clinical and Economic Burden of Newly Diagnosed Hereditary Transthyretin (ATTRv) Amyloidosis: A Retrospective Analysis of Claims Data
INTRODUCTION: Little is known about the burden of hereditary transthyretin (ATTRv) amyloidosis, a genetic, progressive, and fatal disease caused by extracellular deposition of transthyretin amyloid fibrils. The study’s aim was to estimate costs and disease burden associated with ATTRv amyloidosis in...
Autores principales: | Reddy, Sheila R., Chang, Eunice, Tarbox, Marian H., Broder, Michael S., Tieu, Ryan S., Guthrie, Spencer, Vera-Llonch, Montserrat, Pollock, Michael R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606386/ https://www.ncbi.nlm.nih.gov/pubmed/32451849 http://dx.doi.org/10.1007/s40120-020-00194-4 |
Ejemplares similares
-
The patient journey toward a diagnosis of hereditary transthyretin (ATTRv) amyloidosis
por: Vera-Llonch, Montserrat, et al.
Publicado: (2021) -
Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy
por: Magliano, Lorenza, et al.
Publicado: (2021) -
Burden of hereditary transthyretin amyloidosis on quality of life
por: Yarlas, Aaron, et al.
Publicado: (2019) -
Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being
por: Lovley, Andrew, et al.
Publicado: (2021) -
Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2022)